|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A total of 105 consecutive lymph node-negative (N0) HNSCC were evaluated for the presence of venous channel invasion by tumor utilizing the elastin stain.
|
31732985 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This contributes to bioactive matrix fragment (Matrikine) accumulation like elastin degradation products (EDP) stimulating tumour cell invasive and metastatic properties.
|
30739912 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of Elastin-Like Polypeptides for Tumor Targeted Delivery of Doxorubicin to Glioblastoma.
|
31489879 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lysyl oxidases (LOXs) play a central role in extracellular matrix remodeling during development and tumor growth and fibrosis through cross-linking of collagens and elastin.
|
30676771 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lysyl oxidase (LOX) family members play a key role in modifying the primary tumor microenvironment by crosslinking collagens and elastin in the extracellular matrix.
|
30045039 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numbers of elastin stains and tumor-containing blocks were also recorded.
|
28716438 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, YDC002 combined with gemcitabine significantly attenuated the expression of major ECM components including collagens, fibronectin, and elastin in tumor spheroids and xenograft tumors compared with gemcitabine alone, resulting in potent induction of apoptosis, gemcitabine-mediated cytotoxicity, and an oncolytic effect through degradation of tumor ECM.
|
28315430 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, this group of patients also shows the presence of TL-ELNs within the tumor microenvironment and has better survival outcomes.
|
28629479 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, versican siRNA LMS cells, when injected into nude mice, generated smaller tumors that had significantly greater immunohistochemical and histochemical staining for elastin when compared to control tumors.
|
26723257 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study we designed a library of elastin like polypeptide (ELP) polymers containing tumor targeting AP1 peptide using recursive directional ligation method.
|
24339977 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Routine DNA extraction, amplifications at loci D3S 1304 and D3S1537 (both closely distal to VHL, tumour suppressor gene); ELN gene D7S1870; IFNA D1S243 (1p36) which show microsatellite variation.
|
10500829 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lysyl oxidase (LO) initiates the first step in the crosslinking of collagens and elastin and has also been shown to function as a tumor suppressor.
|
9484712 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been found that, while fibroblastic cells of the stroma and of the periductal region are responsible for elastin synthesis in most breast cancers, the malignant epithelium is a source of the elastin in the desmoplastic tissue of a significant proportion of such neoplasms.
|
2156612 |
1990 |